Research synthesis only; not medical advice. The testing methods described are compendial or regulatory standards. No material sold as "research use only" should be assumed safe, sterile, authentic, or suitable for human use. Quality testing for approved products is performed by the licensed manufacturer and regulatory authorities; end users cannot perform meaningful quality assessment without validated methods and reference standards.
Pharmaceutical quality attributes
The quality of a peptide product is defined by a set of critical quality attributes (CQAs) established during development and linked to safety and efficacy:
| Attribute | Meaning | Typical specification |
|---|---|---|
| Identity | The drug substance is the correct peptide, not a different peptide or a degradation product | HPLC retention time, mass spectrum match with reference standard |
| Assay (potency) | The amount of active peptide present, as a percentage of label claim | 95.0--105.0% of label (small molecules); 90.0--110.0% for biologics (may be wider) |
| Purity | Freedom from related substances (degradation products, process impurities) | Individual impurities ≤0.5--2.0%; total impurities ≤2.0--5.0%, product-specific |
| Content uniformity | Each unit contains a consistent amount of drug substance | Meets USP <905> or Ph. Eur. 2.9.40 criteria |
| Sterility | Absence of viable microorganisms | No growth in sterility test (USP <71>) |
| Bacterial endotoxins | Below pyrogenic threshold | Per USP <85>, product-specific limit (e.g., ≤5.0 EU/kg/h for IV products) |
| Particulate matter | Subvisible and visible particles within limits | USP <787>/<788> for subvisible; USP <790> for visible |
| pH | Within labeled range | ±0.3--0.5 units of target |
| Osmolality | Appropriate for route of administration | Typically 270--330 mOsm/kg for isotonic products |
Compendial testing
USP tests applicable to peptide products
| USP General Chapter | Test | Application |
|---|---|---|
<71> | Sterility Tests | All sterile products |
<85> | Bacterial Endotoxins Test | All injectable products |
<151> | Pyrogen Test | Alternative/complementary to <85> |
<787> | Subvisible Particulate Matter in Therapeutic Protein Injections | Biologic injectables |
<788> | Particulate Matter in Injections | All injectable products |
<790> | Visible Particulates in Injections | All injectable products |
<795> | Pharmaceutical Compounding — Nonsterile Preparations | Compounded products |
<797> | Pharmaceutical Compounding — Sterile Preparations | Compounded sterile products |
<905> | Content Uniformity | Dosage units |
<1151> | Pharmaceutical Dosage Forms | General guidance |
Ph. Eur. chapters
| Monograph/Chapter | Test | Application |
|---|---|---|
| 2.6.1 | Sterility | All sterile products |
| 2.6.14 | Bacterial Endotoxins | All injectable products |
| 2.6.30 | Monocyte-activation test | Pyrogen testing |
| 2.9.40 | Uniformity of Dosage Units | Content uniformity |
| 2034 | Products of Fermentation — Ribosomal Peptides | Specific monographs |
Authenticity and counterfeit detection
The scale of counterfeit peptide products
Counterfeit peptide products — those sold with false claims of identity, purity, strength, or origin — are a demonstrated problem, particularly for products sourced from online vendors or outside the regulated supply chain.
Analytical methods to detect counterfeits in post-market surveillance include:
High-performance liquid chromatography (HPLC): Quantitation of main peak; impurity profile compared to reference standard
Mass spectrometry (MS): Exact mass determination, peptide mapping, sequencing
Nuclear magnetic resonance (NMR): Structural confirmation
Infrared (IR) and Raman spectroscopy: Polymorph identification, excipient characterization
X-ray powder diffraction (XRPD): Detection of crystalline vs. amorphous excipients
Immunoassays: ELISA for identity and potency relevant products
Limitations of end-user testing
No end-user (patient or caregiver) can:
Perform any of the above analyses without specialized laboratory equipment and training
Obtain a USP or Ph. Eur. reference standard without proof of legitimate professional need
Interpret results meaningfully without validated specifications
Visual inspection (clarity, color, particulates) and label examination (lot number, expiration date, manufacturer) are the only quality checks accessible to the end user, and they cannot detect subtle chemical degradation, under-dose, or endotoxin.
Container-closure system
The container-closure system (vial, stopper, seal, and, for some products, the device) is a critical quality attribute:
Glass vials: USP Type I borosilicate glass is standard for parenteral products. Delamination (glass flaking) has been reported for certain formulations stored in Type I glass.
Rubber stoppers: Typically bromobutyl or chlorobutyl rubber, coated (B2-42, Flurotec, or similar) to reduce leachables. Stopper formulation must be compatible with the drug product.
Aluminum seals: With plastic flip-off cap; provide tamper evidence and maintain seal.
Vial overfill: A validated manufacturer may use product-specific overfill to account for delivery-system losses; it is not a generic value that can be inferred or used to calculate an unapproved product.
Leachables and extractables
Substances that migrate from container-closure components into the drug product are called leachables (if they appear during storage) or extractables (if forced from the components by aggressive solvents in laboratory studies).
Regulatory guidance (FDA, EMA) requires:
Controlled extraction studies on all container-closure components
Leachable studies on the drug product over its shelf life
Toxicological risk assessment for identified leachables
Sources
USP–NF. Rockville, MD: United States Pharmacopeia; 2026. Chapters:
<71>,<85>,<151>,<787>,<788>,<790>,<795>,<797>,<905>,<1151>.European Pharmacopoeia 11th ed. Strasbourg: EDQM; 2026. Chapters: 2.6.1, 2.6.14, 2.6.30, 2.9.40.
FDA. Guidance for Industry: Container and Closure System Integrity Testing in Lieu of Sterility Testing as a Component of the Stability Protocol for Sterile Products. 2008.
FDA. Guidance for Industry: Chemistry, Manufacturing, and Controls (CMC) Information for Certain Recombinant Therapeutic Products. 2004. https://www.fda.gov/media/72414/download
EMA. Guideline on the Pharmaceutical Quality of Inhalation and Nasal Products. EMA/CHMP/QWP/49313/2005. 2006. https://www.ema.europa.eu/en/pharmaceutical-quality-inhalation-nasal-products-scientific-guideline
FDA. Guidance for Industry: Pyrogen and Endotoxins Testing: Questions and Answers. 2012. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pyrogen-and-endotoxins-testing-questions-and-answers
World Health Organization. WHO guidelines on good manufacturing practices for the manufacture of pharmaceutical products containing biological active substances. WHO Technical Report Series, No. 1020, Annex 3. 2020.
Hall KA, Newton PN. Substandard and counterfeit medicines: a review of the literature. Trop Med Int Health. 2004;9(1):116--130. https://doi.org/10.1046/j.1365-3156.2003.01162.x